|Bid||18.00 x 1000|
|Ask||18.30 x 3000|
|Day's range||17.98 - 19.71|
|52-week range||6.00 - 59.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The original acquisition of Regal was a deal worth around £2.7 billion, or around 23 US dollars per share, in 2017.
According to an agreement, $92 million will be held in escrow and be available to Cineworld as additional liquidity under certain circumstances for the payment, Cineworld said on Friday. Cineworld included $244.2 million in its last annual report, which it said represented the amount payable to a group of Regal's former stakeholders who had challenged whether they received a fair market price for their shares. The company had said the claim was without merit, backing the $23 per Regal share it paid for the $3.6 billion purchase that positioned it as a top competitor to U.S.-listed AMC Entertainment Holdings Inc.
HONG KONG, September 02, 2021--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), today announced that Regencell Bioscience Limited ("Regencell HK"), the Company’s wholly-owned subsidiary in Hong Kong, has entered into a joint venture agreement with Honor Epic Enterprises Limited ("Honor Epic"). The joint venture ("JV") is expected to offer COVID-19 ("COVID") related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.